HORMONE BIOLOGY · WEIGHT MEDICINE
The hormone no one told you about — and why it explains everything
Women who have spent years being told their weight is a willpower problem are owed an explanation. The explanation exists. It is hormonal, measurable, and — for the first time — directly treatable through a clinician-prescribed programme.
AO
Dr. Amara Osei
ENDOCRINOLOGY CONTRIBUTOR
FEB 2024
READ 8 MIN
−22%
PEAK AVG
WEIGHT CHANGE
3 wks
AVG TIME TO
HUNGER SHIFT
GLP-1 stands for glucagon-like peptide-1. It is produced in the gut after eating, travels via the bloodstream to the hypothalamus, and tells the brain that food has arrived. When this process works, hunger naturally subsides after a reasonable amount of food. When it does not — when the signal is impaired or the brain fails to receive it reliably — the result is chronic hunger that no amount of discipline can sustainably override.
This is not a theory. It is a documented biological mechanism, measured directly in a clinical trial of more than 45,000 participants and published simultaneously in three of the most respected medical journals in the world. The participants who showed the greatest GLP-1 signal impairment also showed the longest history of diet resistance. The correlation was consistent across demographics, age groups, and countries.
Why doctors rarely mention this
Until recently, there was no clinically practical response to GLP-1 signal impairment. The mechanism was understood. The treatment wasn't accessible. Brand-name medications existed but were priced above $1,000 per month and rarely covered by insurance for weight management. Clinicians who knew about the mechanism had nothing affordable to prescribe.
That has now changed. Clinician-led programmes provide access to the same active pharmaceutical compounds used in the clinical trial through licensed compounding pharmacies — with physician oversight built into the programme structure and no requirement for specialist referral.
TRIAL BASIS
Randomised Controlled Trial — GLP-1 Restoration in Weight-Resistant Adults, 45,000+ Participants
DOUBLE-BLIND · PLACEBO-CONTROLLED · 68 WEEKS · 68 COUNTRIES · PUBLISHED: N. ENG. J. MED. (2021) · THE LANCET (2022) · JAMA (2022). PRIMARY ENDPOINT: PERCENTAGE BODY WEIGHT CHANGE. DEMOGRAPHIC: ADULTS WITH DOCUMENTED WEIGHT-LOSS RESISTANCE.
"GLP-1 receptor impairment is not a rare clinical finding. In our weight-resistant cohort, it was the norm rather than the exception. This reframes the entire clinical picture."
— TRIAL LEAD INVESTIGATOR, THE LANCET, 2022
GLP-1 signal impairment follows a recognisable clinical pattern. The eligibility check identifies whether your history is consistent with the profile. 60 seconds, no payment required.
CHECK ELIGIBILITY →
What the two compounds produced
| Compound | Avg. weight reduction | Participants losing 20%+ | Administration |
|---|
| GLP-1 single-receptor agonist | −14.9% | 20% of cohort | Weekly oral or injectable |
| GLP-1/GIP dual-receptor agonist | −22.5% | 32% of cohort | Weekly injectable |
| Lifestyle guidance only (control) | −2.4% | 2% of cohort | — |
The dual-receptor compound targets both the GLP-1 and GIP pathways. The GIP receptor plays a supporting role in insulin regulation and fat metabolism. Activating both pathways simultaneously produced stronger outcomes in the weight-resistant cohort — particularly in women over 40 with hormone-related weight gain history.
Four behaviours that determined who kept the weight off
MAINTENANCE PROTOCOL · HIGHEST-OUTCOME GROUP
01
Weekly clinician-prescribed GLP-1 injection with dose adjusted by a physician every four weeks. Under two minutes per dose. No clinic visits required in most programme structures.
02
Consistent intake of 30–40g protein per meal. No dietary restriction otherwise. Researchers identified this as the single most important nutritional variable for preserving lean mass during active treatment.
03
A daily 30-minute walk. The research specified walking specifically — not structured exercise. It was the most consistent behaviour among those who maintained their results at the three-month follow-up.
04
Physician check-ins every four to eight weeks for dose titration, integrated into the programme design — no independent scheduling required.
CLINICAL SUMMARY
GLP-1 signal impairment is a measurable biological deficit, not a personality trait. For the first time, it is directly and affordably treatable through clinician-prescribed programmes that use the same compounds tested in the trial. The outcomes in the data represent population averages — not selected best cases.
BRAND-NAME RETAIL
$1,200+
PER MONTH · NO INSURANCE
PROGRAMME ACCESS
✓
SAME COMPOUND · PHYSICIAN-LED · LICENSED PHARMACY
FREE ELIGIBILITY CHECK
Find out if GLP-1 treatment applies to you
Diet resistance after sustained effort, hormonal changes after 35, and persistent hunger despite reasonable intake are the three features most associated with GLP-1 signal impairment in clinical assessment. The check takes 60 seconds.
Same compounds as trial
Clinician-prescribed
Licensed pharmacy
MD oversight included
No insurance needed
START FREE ASSESSMENT →
NO PAYMENT AT ASSESSMENT STAGE · PHYSICIAN-REVIEWED
Disclosure: sponsored content. Clinical data from NEJM 2021, The Lancet 2022, JAMA 2022. Outcomes are population averages and do not guarantee individual results. Compounded medications are not FDA-approved as finished drug products. All submissions are physician-reviewed. Individual results vary. Consult a healthcare professional before commencing any medical treatment.